The upregulated expression of RIPK2 and activation of inflammatory mediators, especially the hyperactivated stage of NF-κB signaling in IBC makes it more reasonable for synergy between RIPK2 inhibitors and ICIs. The gene discussed is RIPK2; the disease is inflammatory breast carcinoma.